Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure
PharmaShots
APRIL 25, 2023
Founded Year: 2007 Total Employees: ~100 Headquarters: Pennsylvania, United States Market Cap: $477.1M This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. R&D Expenditure: $84.4M R&D Expenditure: $85.1M R&D Expenditure: $437.9M
Let's personalize your content